• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Front Immunol . A potent, broadly neutralizing human monoclonal antibody that efficiently protects hACE2-transgenic mice from infection with the Wuh

tetano

Editor, Senior Moderator
Front Immunol


. 2024 Jul 19:15:1442160.
doi: 10.3389/fimmu.2024.1442160. eCollection 2024. A potent, broadly neutralizing human monoclonal antibody that efficiently protects hACE2-transgenic mice from infection with the Wuhan, BA.5, and XBB.1.5 SARS-CoV-2 variants

Sergey V Guselnikov[SUP] #[/SUP][SUP] 1 [/SUP], Konstantin O Baranov[SUP] #[/SUP][SUP] 1 [/SUP], Sergey V Kulemzin[SUP] 1 [/SUP], Tatyana N Belovezhets[SUP] 1 [/SUP], Anton N Chikaev[SUP] 1 [/SUP], Svetlana V Murasheva[SUP] 1 [/SUP], Olga Y Volkova[SUP] 1 [/SUP], Ludmila V Mechetina[SUP] 1 [/SUP], Alexander M Najakshin[SUP] 1 [/SUP], Nikolai A Chikaev[SUP] 1 [/SUP], Pavel P Solodkov[SUP] 1 [/SUP], Maria V Sergeeva[SUP] 2 [/SUP], Alexander V Smirnov[SUP] 3 [/SUP], Irina A Serova[SUP] 3 [/SUP], Oleg L Serov[SUP] 3 [/SUP], Alexander G Markhaev[SUP] 4 [/SUP], Yulia V Kononova[SUP] 4 [/SUP], Alexander Y Alekseev[SUP] 4 5 [/SUP], Marina A Gulyaeva[SUP] 4 5 [/SUP], Daria M Danilenko[SUP] 6 [/SUP], Nariman R Battulin[SUP] 3 5 [/SUP], Alexander M Shestopalov[SUP] 4 5 [/SUP], Alexander V Taranin[SUP] 1 [/SUP]



Affiliations
Abstract

The COVID-19 pandemic has uncovered the high genetic variability of the SARS-CoV-2 virus and its ability to evade the immune responses that were induced by earlier viral variants. Only a few monoclonal antibodies that have been reported to date are capable of neutralizing a broad spectrum of SARS-CoV-2 variants. Here, we report the isolation of a new broadly neutralizing human monoclonal antibody, iC1. The antibody was identified through sorting the SARS-CoV-1 RBD-stained individual B cells that were isolated from the blood of a vaccinated donor following a breakthrough infection. In vitro, iC1 potently neutralizes pseudoviruses expressing a wide range of SARS-CoV-2 Spike variants, including those of the XBB sublineage. In an hACE2-transgenic mouse model, iC1 provided effective protection against the Wuhan strain of the virus as well as the BA.5 and XBB.1.5 variants. Therefore, iC1 can be considered as a potential component of the broadly neutralizing antibody cocktails resisting the SARS-CoV-2 mutation escape.

Keywords: COVID-19; Omicron; SARS-CoV-1; iC1 antibody; in vivo protection.

 
Back
Top Bottom